Why This Recent Total Solar Eclipse Was the First of Its Kind

The Sun's outer atmosphere—the corona—only reveals itself during total solar eclipses, which happen about every 18 months on Earth, and are only visible along a narrow path. These events offer scientists a rare opportunity to observe the Sun's violent surface—but now, they won't have to wait on the cosmos to do so.
On Monday, June 16, the European Space Agency (ESA) announced that its Proba-3 mission created the world's first artificial total solar eclipse. The mission's two satellites, the Occulter and the Coronagraph, autonomously aligned in space to blot out the Sun's surface and capture images of the corona. Proba-3's success won't just expand access to solar data—it also demonstrates an entirely new level of satellite formation flying.
'I was absolutely thrilled to see the images, especially since we got them on the first try,' said Andrei Zhukov, principal investigator for the Association of Spacecraft for Polarimetry and Imaging Investigation of the Corona of the Sun (ASPIICS) at the Royal Observatory of Belgium, according to the ESA announcement.
The agency launched the Proba-3 mission on December 5, 2024, sending the Occulter and Coronagraph to solar orbit. In May, the two satellites achieved something no spacecraft had done before: Occulter and Coronagraph autonomously aligned in space with millimeter (0.04-inch) precision and maintained their relative position for hours without any intervention from ground control.
To create the artificial eclipse, the two satellites had to align with roughly 500 feet (150 meters) between them, allowing Occulter's 4.6-foot (1.4-meter) disc to cast a 3-inch (8-centimeter) shadow on Coronagraph's optical instrument. This blotted out the surface of the Sun from Coronagraph's perspective, allowing it to photograph the wispy corona.
'Our 'artificial eclipse' images are comparable with those taken during a natural eclipse,' Zhukov said. 'The difference is that we can create our eclipse once every 19.6-hour orbit, while total solar eclipses only occur naturally around once, very rarely twice a year. On top of that, natural total eclipses only last a few minutes, while Proba-3 can hold its artificial eclipse for up to 6 hours.'
This first round of coronal images offers a glimpse into the valuable data this eclipse-making mission will produce, according to ESA. Studying the corona is scientifically valuable for a number of reasons. For one, the corona drives solar wind—the continuous flow of charged particles from the Sun into outer space—and explosive jets of highly magnetized plasma called coronal mass ejections. Observing these forces is crucial to understanding solar weather, which can affect Earth's satellites, communication systems, and power grids.
Insights from Proba-3 and subsequent corona-imaging missions could help scientists better prepare for the threat of a severe solar storm. In May, participants from several U.S. agencies ran the first-ever solar storm emergency drill, revealing major shortcomings in scientists' ability to forecast space weather and protect critical infrastructure.
The corona may also hold the answer to a scientific mystery. This outer layer of the Sun's atmosphere extends millions of miles out into space, but somehow reaches temperatures about 200 times hotter than the surface of the Sun. Experts have described this puzzling phenomenon, dubbed the coronal heating problem, as 'one of the most vexing questions in modern solar physics.'
The Proba-3 mission aims to solve this mystery by using Coronagraph's optical instrument to study the corona very close to the Sun's surface, according to ESA. This state-of-the-art instrument reduces the amount of stray light that reaches the detector, allowing it to capture more detail and detect fainter features than traditional coronagraphs have in the past.
'Current coronagraphs are no match for Proba-3, which will observe the Sun's corona down almost to the edge of the solar surface,' said Jorge Amaya, space weather modeling coordinator at ESA, in the agency's announcement. 'So far, this was only possible during natural solar eclipses.'
In addition to conducting valuable solar science, Proba-3 paves the way for autonomous precision formation flying that will be crucial for future multi-spacecraft missions such as ESA's Laser Interferometer Space Antenna (LISA).
Proba-3 will observe the Sun's corona for about two years, capturing images once only possible during rare celestial alignments. The flood of new observations should drastically improve scientists' understanding of our home star—the force that makes life here on Earth possible.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

28 minutes ago

• Yahoo

A simple blood test could offer first reliable diagnosis for ME

A simple blood test could provide the first reliable diagnosis for myalgic encephalomyelitis (ME) and end the lengthy process of trying to identify the debilitating condition, scientists have found. It's thought more than 400,000 people in the UK suffer with the condition, also known as chronic fatigue syndrome (CFS). Pain, brain fog and extreme low energy that does not improve with sleep are just some of the symptoms of ME. There is no cure and the cause is unknown. Currently the only way to diagnose it is by ruling out other illnesses – a long process that can mean patients wait years for a diagnosis. However, researchers at the University of Edinburgh believe they have made a breakthrough. The study published in the Journal EMBO Molecular Medicine used data from the UK Biobank – a large-scale resource based on the health data and biological samples of 500,000 UK participants. Researchers compared blood samples from 1,455 ME patients with more than 131,000 healthy people. They identified differences in cell counts and molecules that differed in concentrations between the two. The differences in samples for the ME patients were related to chronic inflammation, insulin resistance and liver dysfunction. These findings were compared and replicated in data from a group of American patients and healthy controls. Researchers found 116 'biomarkers' for ME in the blood of men and women with the condition. This is a key finding because the condition affects men and women differently. Professor Chris Ponting, of the university's Institute of Genetics and Cancer, said: 'For so long people with ME/CFS have been told it's all in their head. It's not. We see [it] in their blood. 'Evidence of a large number of replicated and diverse blood biomarkers that differentiate between ME/CFS cases and controls should dispel any lingering perception it is caused by deconditioning and exercise intolerance.' These biomarkers did not change when the participants were any more active – consistent with the view graded exercise therapy, which aims to gradually increase activity levels, is unlikely to be helpful. In fact, the largest differences were seen in people who reported post-exertional malaise. This is when the symptoms of the condition become worse even after minor physical effort. Dr Sjoerd Beentjes, of the university's School of Mathematics, said: 'Blood differences are sometimes attributed to reduced activity levels rather than ME/CFS directly. Our study provides strong evidence ME/CFS affects blood traits through paths other than activity.' However, this research is still at an early stage and there is no guarantee a test will be possible, study authors stressed. Professor Kevin McConway, Emeritus Professor of Applied Statistics, Open University, who was not part of the study, said: 'There is a lot more to do.' 'These findings could help in finding a set of blood biomarkers that can reasonably reliably distinguish people with ME/CFS from those who do not have that condition, but that, without a lot of further work, the findings do not in themselves provide such a set of biomarkers,' he added.

Medscape

32 minutes ago

• Medscape

Preemptive TIPS Promising for Fundal Variceal Bleeding

TOPLINE: In patients with cirrhosis and acute fundal variceal bleeding, the use of preemptive transjugular intrahepatic portosystemic shunt (p-TIPS) with a covered stent within 72 hours of initial bleeding resulted in superior outcomes, with a higher probability of patients being free of death or rebleeding at 1 year than those using standard treatment. METHODOLOGY: Researchers conducted a randomised trial across 17 tertiary centres in France to compare two strategies for preventing rebleeding of non-type 1 gastro-oesophageal varices. They included 101 patients with cirrhosis and acute fundal variceal bleeding (mean age, 58.2 years; 80% men) from January 3, 2019, to February 25, 2023, who achieved initial haemostasis with endoscopic glue injection for at least 12 hours. Patients were randomly assigned to either receive p-TIPS within 72 hours of the initial endoscopic glue injection (n = 47) or continue with on-demand glue obliteration combined with non-selective beta blockers (n = 54). The primary composite endpoint was all-cause mortality or clinically significant rebleeding, defined as recurrent melena or haematemesis requiring hospitalisation or blood transfusion or causing a 3 g/dL drop in haemoglobin, within 1 year from the initial haemostasis. Analyses were conducted in the modified intention-to-treat population. TAKEAWAY: The 1-year probability of being free from death or rebleeding was higher in the p-TIPS group than in the glue obliteration and non-selective beta-blocker group (77% vs 37%; hazard ratio, 0.25; P < .0001). The overall survival did not differ significantly between the two groups; however, 37% of patients in the glue obliteration and non-selective beta-blocker group required TIPS after a median of 25 days. The cumulative incidence of hepatic encephalopathy at 1 year was 35% in the p-TIPS group and 32% in the glue obliteration and non-selective beta-blocker group. Complications related to glue injection occurred in 22 procedures, including 13 bleeding episodes, eight glue migrations (three in the p-TIPS group and five in the glue obliteration group), and one case of cardiac decompensation in the p-TIPS group. The number of patients who experienced any adverse or serious adverse event did not differ significantly between the groups, and no deaths were considered related to the treatment. IN PRACTICE: "The results of the present study strongly support the use of p-TIPS in the management of acute gastric variceal bleeding and add an additional argument in favour of TIPS, which improves prognosis by effectively treating the haemodynamic disorders associated with cirrhosis," the authors of the study wrote. "In patients with cirrhosis and bleeding from fundal varices, p-TIPS with a covered stent is associated with markedly decreased death or rebleeding and should therefore be considered as a first-line therapy," they added. SOURCE: This study was led by Jean-Paul Cervoni, MD, Service d'Hépatologie et de Soins Intensifs, CHU Besançon, Besançon, France. It was published online on June 12, 2025, in The Lancet Gastroenterology & Hepatology. LIMITATIONS: A small sample size precluded definitive subgroup analyses (eg, variceal type). An overrepresentation of alcohol-related cirrhosis may have limited the applicability of the findings to other aetiologies. Eight patients in the p-TIPS group were treated beyond the 72-hour window. DISCLOSURES: This study was funded by the French Ministry of Health. Two authors reported receiving payment for lectures and one author reported receiving consulting fees from Gore. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Yahoo

2 hours ago

• Yahoo

Germany updates: Population growth on the decline

Minister wants to see greater German involvement in space exploration Economy Minister Katherina Reiche is in the US for tariff talks Deutsche Welle is getting a new Director General In 2024, Germany's population grew by 0.1%, down on the 0.4% increase witnessed in 2023 Here are the main developments in Germany on Friday, June 20. Guten Morgen from Bonn. Welcome to DW's coverage of developments in Germany on Friday, June 20. Economy Minister Katherina Reiche is in the United States, speaking to Washington officials, as well as German firms, with Donald Trump's tariffs looming large. Elsewhere, Deutsche Welle is to reveal its new Director General on Friday. Stay with us here to keep up with the latest news from Germany.